Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Files An 8-K Other EventsItem 8.01. Other Events
On November 22, 2016, Protalix BioTherapeutics, Inc. issued a press release announcing that the Brazilian National Health Surveillance Agency (ANVISA, Agencia Nacional de Vigilancia Sanitaria) has granted regulatory approval for alfataliglicerase as a long-term enzyme replacement therapy for children four years old and above with a confirmed diagnosis of Type I Gaucher disease. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Press release dated November 22, 2016.
About Protalix BioTherapeutics, Inc. (NYSEMKT:PLX)
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that is approved for marketing in the United States, Brazil, Israel and other markets. The Company developed Elelyso using ProCellEx system and is focused on utilizing the system to develop a pipeline of clinically superior versions of recombinant therapeutic proteins that primarily target pharmaceutical markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company’s product pipeline includes PRX-102, PRX-106, PRX-112 and PRX-110. Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Recent Trading Information
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) closed its last trading session up +0.035 at 0.516 with 167,256 shares trading hands.